This activity features an international panel of experts that review the science underlying therapy strategies, provide updates on the latest data for therapies in development, and critically evaluate the potential role gene therapy may play in patient care, both now and in the future. It is intended for hematologists, pediatric hematologists, and all members of the clinical care team involved in the care of patients with hemophilia. This content was originally presented as a live preconference symposium at the 61st American Society of Hematology Annual Meeting & Exposition in December of 2019.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Most current safety and efficacy data for emerging gene therapy options in hemophilia
  • Have greater competence related to
    • Identifying the role of gene therapy in an evolving treatment paradigm

Moving Beyond Factor: Shifting the Paradigm in Hemophilia
Through Gene Therapy
Authors: Steven Pipe, MD
CME / ABIM MOC Released: 12/20/2019
Valid for credit through: 12/20/2020

The activity is presented through a collaboration between NHF and Medscape and is supported by educational grants from BioMarin, uniQure and Spark Therapeutics.

If you are already registered with Medscape follow this link to access the activity.

If you are not already registered, go to where registration is straightforward and free of charge.




Webinar Tags